Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Blood
|
July 1, 1992
Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy
R L Hornung, D L Longo
Dermatology Nursing
|
October 1, 1992
Practical approaches to pediatric dermatology
R L Hornung, N S Prose
Pediatric Dermatology
|
February 14, 2002
Parental knowledge and practice of primary skin cancer prevention: gaps and solutions
J M Weinstein, P R Yarnold, R L Hornung
Biotherapy (Dordrecht, Netherlands)
|
January 1, 1992
Systemic IL-1 and adjuvant treatment of an experimental tumor. I. Immune status following tumor rechallenge
R L Hornung, S M Kiertscher, H L Mathews
Cancer Research
|
January 1, 1992
Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity
R L Hornung, J W Pearson, M Beckwith, et al.
Cancer Research
|
March 15, 1990
Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer
K F Mace, R L Hornung, R H Wiltrout, et al.
Journal of the National Cancer Institute
|
October 5, 1988
Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta
R L Hornung, H A Young, W J Urba, et al.
Journal of the National Cancer Institute
|
September 6, 1995
Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor
R L Hornung, D L Longo, O C Bowersox, et al.
Therapeutic Immunology
|
February 1, 1995
Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP)
R L Hornung, D L Longo, V L Gowda, et al.
Cancer Research
|
December 15, 1990
Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer
H Futami, R L Hornung, T T Back, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Blood
|
July 1, 1992
Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy
R L Hornung, D L Longo
Dermatology Nursing
|
October 1, 1992
Practical approaches to pediatric dermatology
R L Hornung, N S Prose
Pediatric Dermatology
|
February 14, 2002
Parental knowledge and practice of primary skin cancer prevention: gaps and solutions
J M Weinstein, P R Yarnold, R L Hornung
Biotherapy (Dordrecht, Netherlands)
|
January 1, 1992
Systemic IL-1 and adjuvant treatment of an experimental tumor. I. Immune status following tumor rechallenge
R L Hornung, S M Kiertscher, H L Mathews
Cancer Research
|
January 1, 1992
Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity
R L Hornung, J W Pearson, M Beckwith, et al.
Cancer Research
|
March 15, 1990
Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer
K F Mace, R L Hornung, R H Wiltrout, et al.
Journal of the National Cancer Institute
|
October 5, 1988
Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta
R L Hornung, H A Young, W J Urba, et al.
Journal of the National Cancer Institute
|
September 6, 1995
Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor
R L Hornung, D L Longo, O C Bowersox, et al.
Therapeutic Immunology
|
February 1, 1995
Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP)
R L Hornung, D L Longo, V L Gowda, et al.
Cancer Research
|
December 15, 1990
Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer
H Futami, R L Hornung, T T Back, et al.
Page
of 2